Insmed reported $195.43M in Operating Expenses for its third fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Operating Expenses Change
DBV Technologies DBVT:US USD 20.09M 5.26M
Acelrx Pharmaceuticals ACRX:US USD 7.14M 7M
Alimera Sciences ALIM:US USD 17.01M 431K
Biomarin Pharmaceutical BMRN:US USD 507.76M 13.12M
Cytokinetics CYTK:US USD 133.2M 33.36M
Dynavax Technologies DVAX:US USD 106.34M 21.9M
Gilead Sciences GILD:US USD 4.2B 26M
Heron Therapeutics HRTX:US USD 68.44M 8.69M
Insmed INSM:US USD 195.43M 41.89M
Mirati Therapeutics MRTX:US USD 191.87M 9.31M
Novartis NVS:US USD 10.67B 183M
Ophthotech OPHT:US USD 42.51M 7.24M
Regeneron Pharmaceuticals REGN:US USD 1.71B 34.8M
Sarepta Therapeutics SRPT:US USD 487.06M 42.45M
Seattle Genetics SGEN:US USD 703.1M 72.49M
Ultragenyx Pharmaceutical RARE:US USD 315.77M 84.83M
Vertex Pharmaceuticals VRTX:US USD 1.21B 117.7M